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Objective—The peroxisome proliferator–activated receptor (PPAR) δ regulates systemic lipid homeostasis and inflammation.
However, the ability of PPARδ agonists to improve the pathology of pre-established lesions and whether PPARδ activation
is atheroprotective in the setting of insulin resistance have not been reported. Here, we examine whether intervention with
a selective PPARδ agonist corrects metabolic dysregulation and attenuates aortic inflammation and atherosclerosis.
Approach and Results—Low-density lipoprotein receptor knockout mice were fed a chow or a high-fat, high-cholesterol (HFHC)
diet (42% fat, 0.2% cholesterol) for 4 weeks. For a further 8 weeks, the HFHC group was fed either HFHC or HFHC plus
GW1516 (3 mg/kg per day). GW1516 significantly attenuated pre-established fasting hyperlipidemia, hyperglycemia, and
hyperinsulinemia, as well as glucose and insulin intolerance. GW1516 intervention markedly reduced aortic sinus lesions and
lesion macrophages, whereas smooth muscle α-actin was unchanged and collagen deposition enhanced. In aortae, GW1516
increased the expression of the PPARδ-specific gene Adfp but not PPARα- or γ-specific genes. GW1516 intervention
decreased the expression of aortic proinflammatory M1 cytokines, increased the expression of the anti-inflammatory M2
cytokine Arg1, and attenuated the iNos/Arg1 ratio. Enhanced mitogen-activated protein kinase signaling, known to induce
inflammatory cytokine expression in vitro, was enhanced in aortae of HFHC-fed mice. Furthermore, the HFHC diet impaired
aortic insulin signaling through Akt and forkhead box O1, which was associated with elevated endoplasmic reticulum stress
markers CCAAT-enhancer-binding protein homologous protein and 78kDa glucose regulated protein. GW1516 intervention
normalized mitogen-activated protein kinase activation, insulin signaling, and endoplasmic reticulum stress.
Conclusions—Intervention with a PPARδ agonist inhibits aortic inflammation and attenuates the progression of preestablished atherosclerosis.   (Arterioscler Thromb Vasc Biol. 2014;34:52-60.)
Key Words: atherosclerosis ◼ inflammation ◼ insulin resistance ◼ lipids

T

he principal cause of mortality in patients with type
2 diabetes mellitus is atherosclerosis,1 a chronic inflammatory disease that is the primary precursor underlying most
cardiovascular events.2 Although the molecular and pathophysiological links between type 2 diabetes mellitus and atherosclerosis are not fully understood, a crucial factor is likely
insulin resistance.3 This is, in part, because of the promotion
of multiple independent risk factors associated with cardiovascular disease, including obesity, hypertension, and dyslipidemia.3 Dyslipidemia associated with insulin resistance
is characterized by increased plasma triglyceride (TG)-rich
very-low-density lipoprotein (VLDL) and cholesteryl ester–
rich low-density lipoprotein (LDL), both of which can permeate a compromised endothelium and initiate atherogenesis.3,4

Therapeutic strategies to reduce plasma LDL have proven
effective in reducing cardiovascular events.5 However, a significant unmet medical need persists, making VLDL-lowering
strategies an attractive therapeutic target.

See accompanying editorial on page 5
Subendothelial retention of atherogenic lipoproteins leads
to a series of maladaptive immune responses culminating
in the development of macrophage foam cells.2,4 Foam cells
play a critical role in the progression of fatty streaks toward
more advance lesions. In particular, M1 macrophages secrete
inflammatory effector cytokines such as interleukin (IL)-1β
and tumor necrosis factor-α, driven predominantly by mitogen-activated protein kinase (MAPK) and nuclear factor
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Nonstandard Abbreviations and Acronyms
ER
FoxO1
HFHC
LDL
Ldlr−/−
NF-κB
PPARδ
SM
TG
VLDL

endoplasmic reticulum
forkhead box O1
high fat, high cholesterol
low-density lipoprotein
LDL receptor knockout mice
nuclear factor-κB
peroxisome proliferator–activated receptor δ
smooth muscle
triglyceride
very-low-density lipoprotein
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(NF)-κB signaling.6 However, insulin signaling, namely the
Akt/forkhead box O1 (FoxO1) pathway, may also contribute
to arterial inflammation.4 In vitro, Il1β is a FoxO1 target gene
in macrophages, with fatty acid–induced insulin resistance.7
Despite 1 study reporting the contrary,8 a growing body of evidence suggests that in vivo, arterial insulin resistance directly
promotes atherosclerosis.4 Global deletion of Akt1 in apolipoprotein E–deficient mice accelerated coronary artery disease
and aortic atherosclerosis, concomitant with significant aortic
inflammation.9 Hematopoietic deletion of the insulin receptor in LDL receptor knockout (Ldlr−/−) mice amplified atherogenesis, an effect attributed to impaired macrophage Akt
signaling.10 Furthermore, increased areas of apoptotic macrophages and necrotic core have been visualized in atherosclerotic lesions from patients with type 2 diabetes mellitus.11
Collectively, these studies support the concept that arterial
insulin resistance promotes inflammation and atherogenesis.
Peroxisome proliferator–activated receptors (PPARs) are a
class of ligand-dependant transcription factors involved in the
regulation of metabolic and inflammatory signaling.12 Three
isoforms exist (α, γ, δ), which exhibit overlapping but distinct
patterns of tissue distribution and function.12 Although PPARδ
has been considered the most enigmatic PPAR, this receptor has
emerged as an important regulator of cellular lipid homeostasis
and inflammatory responses.13 In cultured macrophages, PPARδ
activation inhibits both macrophage lipid accumulation and proinflammatory cytokine expression in response to human VLDL.14
Furthermore, TG accumulation was decreased via angiopoietinlike 4–mediated inhibition of macrophage lipoprotein lipase and
enhanced carnitine palmitoyltransferase 1α–stimulated fatty
acid β-oxidation. Attenuated cytokine expression was mediated
through both inhibition of extracellular signal–regulated kinase
1/2 and activation of Akt/FoxO1 signaling.14 In vivo, Lee et al15
demonstrated that macrophage deletion of Pparδ in Ldlr−/− mice
paradoxically decreased atherogenesis. This effect was attributed
to the suppression of atherogenic inflammation by liberation of
the inflammatory repressor protein B-cell lymphoma-6 because
this protein is normally sequestered by the PPARδ/retinoid X
receptor corepressor complex.15 These studies highlight that deletion of Pparδ mimics the liganded state of the receptor, suggesting
that ligand activation may be atheroprotective. However, studies
examining the effects of synthetic PPARδ agonists using prevention protocols in mice have produced a spectrum of results.16–18
In 1 study, administration of the PPARδ agonist GW0742 to
Ldlr−/− mice fed a high-fat diet had no effect on lesion size.16 In

a second study, GW0742 reduced lesion development in female
Ldlr−/− mice,17 although the doses used yielded serum drug levels 2-fold higher than the EC50 values for murine PPARα and
PPARγ,18 raising the possibility that atheroprotection by GW0742
was not PPARδ specific. In Ldlr−/− mice fed a high-fat diet, low
doses of GW0742 prevented the development of angiotensin II–
accelerated atherosclerosis.19 The next-generation PPARδ agonist
(GW1516) at PPARδ-specific doses prevented the development
of atherosclerosis in apolipoprotein E–deficient mice fed a highfat diet, concomitant with reduced aortic inflammatory cytokine
expression.18 Although on balance these studies indicate that
PPARδ-specific agonists prevent the development of atherosclerosis and arterial inflammation, it is unknown whether PPARδ
agonists are atheroprotective in an intervention model with preestablished insulin resistance and atherosclerosis. Furthermore,
the effect of PPARδ activation on lesion pathology, as well as
aortic inflammatory signaling cascades, insulin resistance, and
endoplasmic reticulum (ER) stress, has not been examined.
In the present study, we use C57BL/6J Ldlr−/− mice fed a
high-fat, high-cholesterol (HFHC) diet, a model of diet-induced
dyslipidemia and insulin resistance. After a diet induction phase,
intervention with the addition of the PPARδ-specific agonist
GW1516 to the HFHC diet resulted in reversal of metabolic
dysregulation, including reduced plasma lipids, glucose, and
insulin and improved glucose and insulin tolerance. Intervention
with GW1516 inhibited aortic MAPK and NF-κB signaling,
attenuated aortic inflammation, improved indices of aortic insulin signaling, reduced aortic ER stress, and collectively attenuated the progression of pre-established atherosclerosis.

Materials and Methods
Materials and Methods are available in the online-only Supplement.

Results
GW1516 Improves HFHC-Induced Metabolic
Dysregulation in Ldlr−/− Mice
Male C57BL/6 Ldlr−/− mice were administered an HFHC
diet for 4 weeks. The metabolic effects of intervention with
the PPARδ agonist GW1516 were evaluated after an additional 8 weeks (Figure 1A). GW1516 at 3 mg/kg per day
resulted in GW nonfasting serum concentrations at the end
of the dark and light cycles of 604±72 and 369±26 nmol/L,
respectively, for a mean concentration of 487±50 nmol/L.
This plasma concentration is below the EC50 for murine
PPARγ (1 μmol/L) and well below the EC50 for murine
PPARα (2.5 μmol/L).20 GW1516 intervention significantly
attenuated HFHC-induced weight gain without affecting
caloric intake (Figure IA and IB in the online-only Data
Supplement). GW1516 decreased fasting plasma cholesterol,
TG, and nonesterified fatty acids compared with 4-week
baseline levels, whereas dyslipidemia in mice remaining
on the HFHC diet alone continued to progress (Figure 1B).
Fast protein liquid chromatography analyses demonstrated
that reduced plasma cholesterol in GW1516-treated mice was
because of a significant reduction in VLDL cholesterol and a
modest but not statistically significant reduction in LDL cholesterol (Figure 1C). GW1516 increased high-density lipoprotein cholesterol by 35% (Figure 1C). The GW1516-mediated
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Figure 1. GW1516 intervention improves dietinduced dyslipidemia. Low-density lipoprotein
receptor knockout (Ldlr−/−) mice were fed standard
chow or a high-fat, high-cholesterol (HFHC) diet
for 4 weeks. For a subsequent 8 weeks, chow-fed
mice remained on chow; the HFHC-fed mice either
remained on HFHC alone or HFHC supplemented
with GW501516 (GW1516); 3 mg/kg per day.
A, Experimental timeline for all studies performed.
B, Plasma cholesterol, triglyceride, and nonesterified fatty acid (NEFA) concentrations were measured
at weeks 0, 4, and 12 (8–12/group). Arrows indicate
the time of GW1516 intervention. C and D, Plasma
was subjected to fast protein liquid chromatography
(FPLC) analysis at week 12, and cholesterol and
triglyceride were measured in the eluted fractions
(n=3–5/group). Data are presented as mean±SEM.
In B, different letters indicate significant differences
(P<0.05). In C and D, *indicates significant difference vs HFHC (12 weeks; P<0.05). HDL indicates
high-density lipoprotein; LDL, low-density lipoprotein; and VLDL, very-low-density lipoprotein.
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reduction in plasma TG was because of a substantial 63%
reduction in VLDL-TG (Figure 1D). GW1516 intervention
decreased epididymal fat by 11% compared with 4-week baseline and by 35% compared with mice remaining on the HFHC
diet alone (Figure IC in the online-only Data Supplement),
demonstrating attenuation of adipose tissue accumulation.
GW1516 prevented the increase in fasting blood glucose
(from week 4 to week 12) and completely normalized impaired
glucose tolerance induced by the HFHC diet at 12 weeks
(Figure IIA and IIC in the online-only Data Supplement).
GW1516 intervention reversed both fasting hyperinsulinemia
and impaired insulin tolerance induced by the HFHC diet,
demonstrating normalization of whole-body insulin sensitivity (Figure IIB and IID in the online-only Data Supplement).
This is consistent with the improved glucose tolerance in highfat diet–fed C57BL/6J mice and improved insulin tolerance in
db/db mice after a 2-week intervention with GW1516.21

GW1516 Attenuates Aortic Sinus Atherosclerosis
and Aortic Inflammation in HFHC-Fed Ldlr−/− mice
Examination of aortic sinus atherosclerosis revealed that oil redO–stained lesion area of HFHC-fed mice at 4 weeks progressed
significantly (≈6-fold) by week 12 (Figure 2A and 2C). In contrast, although lesion area continued to increase, the area was
significantly attenuated in GW1516 intervention mice by ≈33%
compared with animals remaining on HFHC alone (Figure 2C).
GW1516 intervention influenced lesion composition. As a percent of total area, lesions of HFHC-fed animals at either 4 or 12
weeks displayed accumulation of monocyte and macrophage
antibody-2–positive macrophages, which was significantly
attenuated by intervention with GW1516 (representative images
are shown in Figure III in the online-only Data Supplement, and

quantification is shown in Figure 2D). No appreciable smooth
muscle (SM) α-actin or collagen deposition was observed in
lesions of HFHC-fed mice at 4 weeks, and values were low in
12-week chow-fed mice (Figure 2E; Figure III in the onlineonly Data Supplement). However, SM α-actin occupied 40% of
lesion area in HFHC-fed mice at 12 weeks, which was similar
to that of GW1516 intervention mice. As assessed by trichrome
staining, the HFHC diet at 12 weeks increased collagen deposition to 25% of lesion area, which was further increased (to
35%) in GW1516 intervention mice (data not shown), despite
no further effect on percent lesion SM cell content (Figure 2E;
Figure III in the online-only Data Supplement).
To further elucidate the effect of GW1516 intervention
on lesion collagen, picrosirius red–stained aortic sinus sections were imaged with circular polarization microscopy to
detect fibrillar collagen22 (Figure 2B). The collagen area fraction of lesions was 24% in HFHC-fed animals and 31% in
lesions of mice subjected to GW1516 intervention (P=0.025;
Figure 2F). This technique also revealed that a collagen-containing fibrous cap existed in lesions in both circumstances
(Figure 2B). To determine whether collagen fiber integrity in
the cap was affected by GW1516 intervention, collagen birefringence was quantified (Figure 2B and 2G). This revealed
a significant 36% increase in the retardation of polarized
light by lesion cap collagen in mice subjected to GW1516
intervention (Figure 2G), denoting more densely packed and
aligned collagen fibrils (Figure 2B, arrows). Lesion apoptosis, assessed by cleaved caspase-3 staining, was detected in
1.7% of cells within lesions from 12-week HFHC-fed mice
(Figure 2H; Figure IV in the online-only Data Supplement).
GW1516 intervention significantly reduced cleaved caspase-3
staining to 1.0% of cells (P<0.05), indicating a reduction in
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Figure 2. GW1516 attenuates high-fat,
high-cholesterol (HFHC)–induced atherosclerosis. A, Representative photomicrographs of aortic sinus sections stained
with oil red-O and counterstained with
hematoxylin. Scale bar, 500 μm. B, Representative photomicrographs of aortic sinus
sections stained with picrosirius red and
imaged using circularly polarizing light and
liquid crystal compensation. Scale bar, 250
μm. Arrows depict birefringent collagen
fibers on the surface of atherosclerotic
lesions, consistent with fibrous caps of
varying organization. Color encoding of light
retardation (nm) is depicted in the gradient
map (blue: low; red: high). C, Quantification
of neutral lipid area (oil red-O); (D) MOMA-2
(macrophages) and (E) smooth muscle (SM)
α-actin (smooth muscle cells) expressed
as lesion area (oil red-O) or % lesion area
(MOMA-2, SM α-actin; n=6–9/group). Representative photomicrographs are available
in Figure III in the online-only Data Supplement for MOMA-2 and SM α-actin. F and G,
Quantification of collagen expressed as %
lesion area (F) and mean collagen fibril light
retardation (G), determined from picrosirius
red–stained sections (B) and visualization
using circularly polarized light (n=8–12/
group). H, Quantification of lesion apoptosis
determined by % caspase-3act–positive cells
relative to total cells in aortic sinus lesions
(n=5–11/group). Representative photomicrographs are available in Figure IV in the
online-only Data Supplement. Staining for
collagen, SM α-actin, and caspase-3act–
positive cells was undetectable in lesions
from HFHC 4-week sections. Values from individual mice are represented by symbols, and the mean is indicated by a single horizontal
line. Different letters indicate significant differences (P<0.05).

apoptotic cells within lesions. Caspase-3act–positive cells were
undetectable in sections from 4-week HFHC-fed mice and
low in chow-fed mice at 12 weeks.
Lipid analyses of full-length aortae from HFHC-fed mice at
12 weeks revealed that TG and total cholesterol mass increased
1.4-fold and 1.6-fold compared with HFHC-fed mice at 4 weeks
(Figure 3A and 3B). GW1516 supplementation decreased aortic TG by 60% compared with the 12-week HFHC cohort and
by 40% compared with the 4-week HFHC-fed mice, but the
latter was not significant. GW1516 decreased aortic total cholesterol by 27% compared with HFHC-fed mice at 12 weeks,
but values remained elevated (30%) compared with HFHCfed mice at 4 weeks. Collectively, these analyses indicate that
GW1516 intervention attenuates lesion progression and results
in development of smaller, lipid-depleted, more stable lesions.
A panel of cytokines known to modulate atherogenesis
was examined in full-length aortae. After 4 weeks of HFHC
feeding, only chemokine (C-C motif) ligand 3 (Ccl3) and
intercellular adhesion molecule-1 (Icam1) expressions were
increased compared with chow-fed controls, which is indicative of monocyte recruitment without overt inflammation
(Figure 3C). However, the expression of proinflammatory
M1 cytokines Ccl3, II1b, Icam1, tumor necrosis factor (Tnf),
II6, and chemokine (C-C motif) ligand 2 (Ccl2) was markedly induced (2- to 25-fold) in the aortae of HFHC-fed mice
at 12 weeks. In contrast, although all cytokines were elevated
in GW1516-treated mice compared with HFHC-fed mice at

4 weeks, cytokine expression was significantly lower (−25%
to −85%; mean, −60%) compared with HFHC-fed mice at
12 weeks (Figure 3C). Although monocyte and macrophage
antibody-2–stained macrophages within lesions decreased
≈25% in GW1516-treated mice, the greater reduction in
cytokine expression suggests that macrophages remaining
in lesions of GW1516-treated mice were less inflammatory.
Furthermore, compared with 4 weeks, 12-week HFHC feeding
significantly increased the aortic expression of the M1 marker
inducible nitric oxide synthase (iNos) (3-fold) and suppressed
the expression of the anti-inflammatory M2 marker arginase 1 (Arg1) (−53%), resulting in an exacerbated iNos/Arg1
ratio (20-fold; Figure 3D). GW1516 intervention completely
reversed this expression pattern. Together, these data indicate
that in PPARδ agonist–treated mice, lesion macrophage content is lower (Figure 2D) and there is a shift from M1 to M2
cytokine expression, suggesting an increase in the proportion
of macrophages with M2 polarization.
We examined cell signaling cascades known to regulate the
macrophage inflammatory response.6 Compared with HFHCfed mice at 4 weeks, activation of extracellular signal–regulated kinase 1/2 and p38 was observed in full-length aortae
of HFHC-fed mice at 12 weeks (Figure 4A). Phosphorylated
extracellular signal–regulated kinase 1/2 and phosphorylated
p38 were significantly lower in GW1516-treated mice, indicating that GW intervention inhibits the development of activated
MAPK signaling. We observed a marked induction of aortic
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Figure 3. GW1516 attenuates lipid accumulation
and M1 macrophage markers and induces a shift
toward M2 macrophage markers in full-length
aortae. A and B, Triglyceride (TG) and total cholesterol (TC) concentrations were determined in aortic
extracts (n=5–7/group). C, mRNA abundance of
the indicated proinflammatory M1 cytokines and
(D) the anti-inflammatory M2 cytokine Arg1 and the
Arg1/iNos ratio, determined in full-length aortae
dissected free of fat and connective tissue (n=4–6/
group). Data are presented as mean±SEM. Different letters indicate significant differences (P<0.05).
HFHC indicates the high fat, high cholesterol diet.
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NF-κB signaling in HFHC-fed mice at 12 weeks, as demonstrated by increased phosphorylated inhibitor of nuclear factor κ-B kinase and phosphorylated inhibitor of nuclear factor
of κ light chain gene enhancer in B-cells, α (Figure 4B). In
contrast, GW1516 intervention attenuates NF-κB activation
(Figure 4B). This suggests that GW1516 diminishes aortic
inflammation, in part, by attenuating diet-induced activation
of inflammatory signaling cascades.

GW1516 Intervention Corrects Diet-Induced
Aortic Insulin Signaling and ER Stress and
Exerts PPARδ-Specific Vessel Wall Effects
Genetic manipulations resulting in impaired insulin signaling in hematopoietic cells exacerbate atherosclerosis, partly

because of increased aortic inflammation and ER stress.4,9,10
We, therefore, hypothesized that impaired aortic insulin signaling contributed to the proinflammatory phenotype of aortae
in HFHC-fed mice. Aortic phosphorylated Akt and phosphorylated FoxO1 in fasted and acutely refed mice were examined
after the 8-week intervention phase. Compared with chow-fed
mice, phosphorylated Akt and phosphorylated FoxO1 were
higher in aortae from fasted HFHC-fed mice, but in contrast
to chow-fed mice were not further increased by refeeding
(Figure 5A). GW1516 intervention completely restored the
fasting-to-feeding dynamic regulation of phosphorylated Akt
and phosphorylated FoxO1 to patterns observed in chowfed controls (Figure 5A). The Src homology 2 domain–
containing tyrosine phosphatase-1 is primarily expressed

Figure 4. GW1516 corrects aberrant mitogen-activated protein kinase and nuclear factor-κB signaling
in full-length aortae of high-fat, high-cholesterol
(HFHC)–fed mice. A, Representative immunoblots
of phosphorylated (p) extracellular signal–regulated
kinase (ERK) 1/2 and p-p38 with quantification
(mean±SEM) for n=4 to 6/group. Bands from
HFHC-fed mice at 4 weeks are from a different
immunoblot, whereas bands for the other groups
are from the same immunoblot cut from different
regions. B, Representative immunoblots of pIKK
and pIκBα with quantification (mean ±SEM) for
n=4 to 6/group. Representative bands are from the
same immunoblot cut from different regions. A and
B, Results are expressed as fold change relative to
values for chow-fed mice at 12 weeks. Different letters indicate significant differences (P<0.05).
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Figure 5. GW1516 corrects aberrant insulin signaling and endoplasmic reticulum (ER) stress in aortae
of high-fat, high-cholesterol (HFHC)–fed mice.
Immunoblotting or quantitative reverse transcriptase polymerase chain reaction was performed on
full-length aortae. A, Representative immunoblots
of phosphorylated AKT (pAKT) and phosphorylated
forkhead box O1 (pFoxO1) in aortae from 1 mouse
fasted for 16 h (designated F) and 1 or 2 mice
fasted for 16 h followed by a 2-h refeeding period
(designated RF). Quantification is shown for n=6
to 8/group. B, mRNA abundance of the negative
regulator of insulin signaling Ptpn6 (n=4–6/group).
C, Representative immunoblots of Src homology
2 domain–containing tyrosine phosphatase (SHP1; the protein product of Ptpn6). Quantification
is shown for n=4 to 6/group. D, Representative
immunoblots of ER stress markers GRP78 and
CHOP. Quantification is shown for n=4 to 6/group.
E, mRNA abundance of the negative regulator of
insulin signaling Trib3 (n=4–6/group). Data are presented as mean±SEM. A, C, and D, For immunoblot
quantification, results are presented as fold change
relative to values for chow-fed mice at 12 weeks.
In A, different upper case letters indicate statistical significance among fasted animals, different
lower case letters indicate statistical significance
among refed animals, and an asterisk (*) indicates
statistical significance between fasted and refed
mice within the same diet (P<0.05). In B to E, different letters indicate significant differences (P<0.05).
Representative bands are from the same immunoblot cut from different regions.

Downloaded from http://ahajournals.org by on June 22, 2022

by hematopoietic cells and is a known negative regulator of
hepatic insulin signaling.23 Aortae from HFHC-fed mice at
12 weeks were significantly enriched for the Src homology 2
domain–containing tyrosine phosphatase-1 transcript (Ptpn6;
5-fold) and Src homology 2 domain–containing tyrosine
phosphatase-1 protein (30-fold), both of which were strongly
attenuated by GW1516 intervention (Figure 5B and 5C).
Concomitant with dysregulated aortic insulin signaling was
a significant increase in ER stress markers GRP78 and CHOP
in aortae of HFHC-fed mice at 12 weeks (Figure 5D). The
CHOP target gene and negative regulator of insulin signaling,
tribles homolog 3 (Trib3),24 was also elevated (Figure 5E).
GW1516 intervention restored GRP78, CHOP, and Trib3 to
levels observed in chow-fed controls (Figure 5D and 5E).

To determine whether GW1516 exerted effects directly
within the aorta, we examined the expression of known PPARδ
target genes. Expression of adipose differentiation related protein (Adfp), angiopoietin-like 4 (Angptl4), and carnitine palmitoyltransferase (Cpt)-1α was significantly increased in aortae
of GW1516-treated mice compared with HFHC-fed mice or
chow-fed controls at 12 weeks (Figure 6A). Expression of
target genes specific for PPARα (acyl-CoA oxidase [Acox])
and PPARγ (lipoprotein lipase [Lpl] and fatty acid binding
protein 4 [Fabp4]) was unaffected by GW1516 intervention
(Figure 6B). Similar results were observed in liver (data not
shown). This indicates that GW1516 exerts a direct effect on
the arterial wall, which likely contributes to attenuation of aortic inflammation, insulin resistance, and ER stress, as well as

Figure 6. GW1516 activates aortic peroxisome proliferator–activated receptor (PPAR) δ but not PPARα
or PPARγ. A, mRNA abundance of PPARδ target
genes Adfp, Angtpl4, and Cpt1a and (B) PPARα target genes Acox and Lpl and the PPARγ target gene
Fabp4 in full-length aortae (n=4–6/group). Data are
presented as mean±SEM. Different letters indicate
significant differences (P<0.05). HFHC indicates the
high fat, high cholesterol diet.
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lesion progression. These data further indicate that with respect
to PPARs, the aortic effects of GW1516 are PPARδ specific.

Discussion
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The risk of atherosclerosis is elevated approximately 4-fold in
adults with type 2 diabetes mellitus.1 Despite this, therapeutic
strategies to alleviate atherosclerosis associated with insulinresistant syndromes remain sparse. Here, we demonstrate in
mice that intervention with a synthetic PPARδ agonist, in the
context of diet-induced dyslipidemia and insulin resistance,
attenuates the progression of early stage lesions to larger
plaques. PPARδ activation was associated with beneficial
changes in lesion composition, including fewer macrophages,
increased expression of M2 markers, less lipid, increased collagen, decreased ER stress, and fewer apoptotic cells, characteristic of lesions with a more stable phenotype. Furthermore,
we show that in HFHC-fed mice, the aberrant inflammatory
response and impaired insulin signaling within the aorta are
reversed by PPARδ activation.
Dyslipidemia associated with insulin resistance is characterized by elevated plasma VLDL and LDL, concomitant
with reduced plasma high-density lipoprotein.3 Although
statins effectively lower plasma LDL, they do not fully correct other features of atherosclerosis risk, namely elevated
plasma VLDL, decreased high-density lipoprotein, insulin
resistance, and body fat composition.25 The present study
demonstrates that intervention by a PPARδ agonist corrects
previously established metabolic disturbances. Although
plasma LDL cholesterol was modestly reduced, PPARδ activation primarily targeted plasma VLDL and high-density
lipoprotein. This is consistent with human studies demonstrating that PPARδ agonists correct mixed dyslipidemia in
patients with metabolic syndrome.26,27 The current study contributes to the plausibility of PPARδ agonists as therapeutic
agents for metabolic dysregulation associated with insulin
resistance. Whether PPARδ agonists will have an effect in a
setting where elevated LDL is a primary determinant of atherosclerosis remains to be determined.
We recently demonstrated in cultured macrophages that
PPARδ activation attenuates VLDL-induced TG accumulation and proinflammatory cytokine expression.14 We extend
these in vitro findings, demonstrating that GW1516 intervention prevents further increase in aortic TG, in concert with
significant induction of the PPARδ target genes Angptl4 and
Cpt1a. This suggests that GW1516 may stimulate aortic fatty
acid β-oxidation and inhibit aortic lipoprotein lipase activity,
thus contributing to reduced atherogenesis. We provide evidence that inflammatory cells within the aortae of HFHC-fed
animals were polarized to the proinflammatory M1 phenotype.28,29 Furthermore, GW1516 intervention increased the
anti-inflammatory M2 state,28,29 consistent with reports demonstrating that alternative M2 activation of adipose tissue
macrophages and hepatic Kupffer cells is, in part, mediated
by PPARδ.30,31 M2 macrophages are thought to contribute to
tissue remodeling and repair29 and are increased in lesions
undergoing regression.32 Although GW1516 did not induce
size regression of early lesions, the M2 phenotype was associated with significant slowing of lesion progression. Longerterm studies are required to assess the effect of PPARδ

agonists on more advanced stage lesions. Nevertheless, the
present study demonstrates that PPARδ activation alleviates
aortic lipid accumulation and inflammation, thus contributing
to attenuated lesion development.
That GW1516 increased lesion collagen deposition without altering percent SM cell content is possibly as a result of
PPARδ activation of the synthesis and deposition of extracellular matrix by lesion SM cells. This hypothesis is consistent
with a report that PPARδ activation in cultured vascular SM
cells inhibits IL-1β–induced matrix metalloproteinase-2 and
matrix metalloproteinase-9 expression.33 Reduced lipid deposition in vascular SM cells restores their capacity to elaborate
extracellular matrix.34,35 Thus, the ability of PPARδ agonists to
improve the function of lipid-loaded vascular SM cells merits
further attention.
The MAPK and NF-κB signaling pathways regulate inflammatory cytokine expression.6 In the aortae of HFHC-fed animals, both signaling cascades were significantly activated.
GW1516 intervention substantially blunted these changes. In
cultured cardiomyocytes, the PPARδ agonist GW0742 attenuated lipopolysaccharide-induced NF-κB activation through
increased IκB expression, thereby inhibiting nuclear translocation of NF-κB.36 We did not observe appreciable changes
in total aortic IκB protein. Thus, the mechanism by which
PPARδ inhibits NF-κB activation in the context of aortic inflammation remains to be determined. With respect to
MAPK activation, GW0742 inhibited angiotensin II–induced
phosphorylation of extracellular signal–regulated kinase
1/2 and p38 in cultured mouse macrophages via upregulation of regulator of G-protein signaling (Rgs)-4 and Rgs5.19
Consistent with this report, we observed a significant upregulation of both Rgs4 and Rgs5 in aortae of GW1516-treated
mice compared with aortae of HFHC-fed mice (Figure V in
the online-only Data Supplement). Collectively, our intervention studies suggest that PPARδ activation within the aorta
dampens inflammatory signaling, leading to attenuation of
inflammatory cytokine expression.
Impaired insulin signaling in the vasculature has emerged
as a major contributor to lesion progression.4 In mice, macrophage deletion of the insulin receptor accelerated the development of advanced lesions,10 and loss of Akt1 led to severe
atherosclerosis.9 Endothelial cell–specific deletion of 3 FoxO
isoforms resulted in atheroprotection, attributed, in part, to
an anti-inflammatory effect.37 Although these gene deletion
models highlight the significance of vascular insulin signaling in atherogenesis, these studies do not identify whether
insulin signaling becomes dysregulated during lesion development.38 Here, we demonstrate that mice with diet-induced
atherosclerosis exhibit impaired aortic insulin signaling, as
evidenced by loss of dynamic fasting-to-refeeding regulation
of both Akt and FoxO1 phosphorylation, coupled to an induction of negative regulators of insulin signaling, Src homology
2 domain–containing tyrosine phosphatase-123 and Trib3.24
This suggests that the loss of insulin regulation of both Akt
and FoxO1 results in FoxO1 target genes such as Il1b7 being
chronically transcribed rather than dynamically regulated.
This mechanism may contribute to the accumulation of proinflammatory mediators within the vessel wall, inducing a state
of chronic low-grade inflammation. Impaired aortic insulin
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signaling was also correlated with elevations in ER stress
markers GRP78 and CHOP. Furthermore, activation of aortic
PPARδ restored dynamic insulin signaling and attenuated ER
stress. It is important to note that the presence of arterial insulin resistance did not impair the ability of GW1516 to attenuate pre-established lesion progression. Thus, although difficult
to quantify, it remains possible that improved insulin signaling
within GW1516-treated aortae contributes to atheroprotection.
In this study, a major factor in the attenuation of lesion
development by intervention with GW1516 is reduction of
plasma lipids, particularly VLDL/intermediate-density lipoprotein, thereby reducing the atherogenic stimulus. However,
we demonstrate that in the aorta, GW1516 stimulates PPARδspecific target genes, which are known to improve macrophage
lipid homeostasis and attenuate the inflammatory response.
Although these effects likely contribute to the observed reduction in atherosclerosis, further studies are required to elucidate
the extent to which improved metabolic parameters versus
direct vessel wall effects contribute to PPARδ-mediated atheroprotection. Nevertheless, the current study provides strong
evidence that intervention to an HFHC diet with a PPARδ
agonist suppresses and favorably modifies the HFHC diet–
induced progression of early lesions. It will be important to
determine whether intervention by PPARδ activation improves
the pathology of more advanced lesions and whether extended
treatment achieves regression. We conclude that PPARδ activation remains a viable therapeutic target for atherosclerosis
prevention and treatment.
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Significance
Vascular insulin resistance has been postulated to accelerate atherogenesis by increasing inflammation and endoplasmic reticulum stress.
The peroxisome proliferator–activated receptor (PPAR) δ is a ligand-dependent transcription factor that regulates insulin sensitivity, lipid
homeostasis, and inflammation. We demonstrate for the first time that intervention with a PPARδ agonist, in the context of diet-induced
dyslipidemia and insulin resistance, attenuates the progression of early stage lesions to larger plaques. PPARδ activation was associated
with beneficial changes in lesion composition, including fewer macrophages, increased M2 cytokine expression, less lipid, increased collagen, decreased endoplasmic reticulum stress, and fewer apoptotic cells, characteristic of more stable lesions. Furthermore, we show that
in high-fat, high-cholesterol–fed mice, the inflammatory response and insulin signaling within the aorta are impaired, but these abnormalities
are reversed by PPARδ activation. Collectively, these findings highlight a role for PPARδ agonists in the prevention and treatment of atherosclerosis, even in a setting of pre-established insulin resistance and atherosclerosis.
Downloaded from http://ahajournals.org by on June 22, 2022

